Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | INCB106385 |
Trade Name | |
Synonyms | INCB-106385|INCB 106385 |
Drug Descriptions |
INCB106385 is a dual inhibitor of A2A and A2B receptors, which may prevent immune suppression in the tumor microenvironment and promote anti-tumor immune response (AACR Annual Meeting Apr 2020, Session PO.IM02.03, Abstract # LB157). |
DrugClasses | Adenosine Targeting 23 |
CAS Registry Number | NA |
NCIT ID | C178440 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
INCA00186 + INCB106385 | INCA00186 INCB106385 | 0 | 1 |
INCA00186 + INCB106385 + Retifanlimab | INCA00186 INCB106385 Retifanlimab | 0 | 1 |
INCB106385 | INCB106385 | 0 | 1 |
INCB106385 + Retifanlimab | INCB106385 Retifanlimab | 0 | 1 |